U.S. Markets closed

Roche Holding AG (RHHBY)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
33.96-0.41 (-1.19%)
At close: 4:00PM EDT
People also watch
NVSSNYNSRGYAZNBAYRY
  • Charles A. Henriques
    NeurogesX Inc.15% owner. QUTENZA developer - Non-Opioid Pain Therapies For Unmet Needs In Neuropathic Pain

    Neuropathic Pain Investor Sacred Heart University Fairfield CT BS/BA Business Administration

    San Francisco Bay Area 500+ 500+757 connections linkedin.com

    Charles A. Henriques increased stake in NeurogesX, Inc. Filed SC 13G/A form with U.S. Securities and Exchange Commission on February 13, 2017. Amount beneficially owned: 4,966,649 NGSX shares. CUSIP# 641252101.

    Form 13G is used when the filer owns between 5% and 20% of the company and plans to hold it only as a passive investor. If the filler intend to exert control and if the stake’s size exceeds 20%, then a 13D must be filed. Therefore, activist investors and practices such as: hostile takeovers, company breakups, and other “change of control” events, are not permitted by 13G filers.

    NeurogesX Inc. (NeurogesX), is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, Pain Management Therapies to address unmet medical needs. Qutenza the Company’s first commercial product, has FDA approval, available in USA by Acorda Therapeutics Inc. EU approval in 2009 and available at Astellas Pharma in all 28 European countries.

    Qutenza is a dermal delivery system designed to topically administer capsaicin to treat certain neuropathic pain conditions. Approved by the FDA for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In September 2015, the European Commission approved a label extension for Qutenza to include diabetic patients with neuropathic pain, adding more value to product.

    QUTENZA has a Patented Synthetic Capsaicin that works faster and better than Lyrica according to a study published in the European Journal of Pain, funded by Astellas Pharma Europe Ltd,

    Lyrica is Pfizer’s top selling drug with annual worldwide sales of over $5 billion.

    Grunenthal News 12 -12 -17 Acquiring Commercialization Rights for Qutenza® From Astellas.

    The Grünenthal Group is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen,
  • Did Rhhby pay its dividend on 4/22/17. I have not received the dividend yet
  • When is the dividend day?3/17 is the ex-dividend day.
  • Imagearchiemcphee
  • I mean 3/15 is ex...
  • Bioprinting advances from Aether and Nano Dimension
    The 3D bioprinting market is gaining momentum with several recently developments. Israeli PCB 3D printer and ink company Nano Dimension (NASDAQ: NNDM) has made a further advance with a new patent for 3D inkjet printing with living cells. And San Fran
    3dprintingindustry.com
  • Posted in $GALT conversation
    This is an interesting article and I do believe it could happen for the company soon. In the biotech sector, we could be about to see a case of history repeating. Could Galectin Therapeutics Inc (NASDAQ:GALT) be Tobira 2.0? NASH is a chronic liver disease. Before you get NASH, you get something called nonalcoholic fatty liver disease (NAFLD), which is an accumulation of fat in spots where cells have died due to inflammation. NASH slowly transitions into fibrosis (could take up to two decades in some extreme cases) and then transitions to cirrhosis in about 25% of patients. This disease is thought to cause damage on the order of $600M a year. There are no drugs currently approved to treat this disease. As the population increases, so will the market for NASH treatment which is estimated to be $1.3 Bill in 2017. There is a race to be first to market with a viable treatment and Galectin Therapeutics Inc (NASDAQ:GALT) with its galectin inhibitors is a prime candidate. This is a drug with an attractive valuation which is arguably even better than Tobira’s was before its buyout.

    Let’s look at the Tobira acquisition by Allergan ($AGN). They bought the company in Phase 3 even as it was failing to meet clinical endpoints, for $1.7 billion. Contrasted with GALT, which is presently finishing up its phase II study- if the endpoints of this study are met within the next 10 months, it is a virtual lock for regulatory approval. Comparable valuation of this company could be close to $1.7 billion, which would represent a target price of $53/share.

    There is also a billionaire investor involved with Galectin Therapeutics Inc (NASDAQ:GALT): Richard Uihlein. He owns Uline, a shipping supplies company. He was very influential in getting republican Scott Walker elected as governor of Wisconsin, and was named one of the top 20 most powerful political insiders. His initial investment was a year after the NASDAQ listing at $6/share, with additional investments after the FX trial in 2016, and another at the end of 2016. His total stake in the company approaches 8%. Even more impressive and telling is that he didn’t sell when the stock was at $19.

    When you really look closely at GALT you see that it is the ONLY public company with a galectin blocker drug even close to marketing approval. At the GTC Bio Conference, GALT’s results excited investors as their Galectin Blocker GM-MD-02 pits 3 drug giants, Merck ($MRK), Bristol Meyers ($BMY), and Roche ($RHHBY) against each other to make a play on these assets.

    The pipeline at GALT is impressive because Galectins are implicated in so many chronic diseases, including cancer. NASH is only one subset of liver disease. What about Alcoholic Liver Disease (ALD)? The same mechanism of action that reversed fibrosis in NASH could also work in ALD. Almost all organ fibrosis is linked to the Galectin-3 receptor, so that means Pulmonary, Kidney, and Heart disease could come next.

    It doesn’t take much imagination to see the potential of this company on so many fronts. GALT has more going for it than Tobira. They have a safer drug with more robust preclinical data. The company has a platform technology that once approved can go over multiple indications in organ fibrosis and cancer. On top of all that, the stock is extremely undervalued. Tobira went from under $2 to $44, and when it’s all said and done… GALT could be next Tobira, or as we’ve deemed it- Tobira 2.0!

    Despite all of the tantalizing facts on GALT that you read above, the reality remains that it is mostly speculation at this point, without so much as a credible rumor of a buyout so far. That being said, it’s always important to use your powers of foresight, and as we laid out here, GALT is a prime candidate for a future deal that could see it go the way of Tobira. We’ll be sure to keep our ears to the tracks here on Street Register, and pass along any new developments that occur in GALT. Be sure you’re signed up to our 100% free penny stock newsletter to stay up to date with GALT, by simply entering your email into the box below and hitting Subscribe Now!
  • NBC right now for news on their MS rugs
  • Let's see a breakthrough day today!
  • https://www.ucsf.edu/news/2017/03/406296/new-multiple-sclerosis-drug-ocrelizumab-could-halt-disease

    New Multiple Sclerosis Drug, Backed by 40 Years of Research, Could Halt Disease
    A newly approved drug that is the first to reflect the current scientific understanding of multiple sclerosis is holding new hope for the hundreds of thousands Americans living with the disease. It also highlights the importance of clinician scientis
    www.ucsf.edu
  • where s Carl Icahn when we need him? Need to break this company up. To do otherwise is costing shareholders $$$ hundreds millon lost
  • Will Roche use this brand new revolutionary 3D bioprinter?

    3Dprint.com says Aether will "Absolutely transform the entire bioprinting market"

    https://3dprint.com/165599/aether-bioprinter-u-of-cambridge/

    First Beta Unit of the Aether 1 Bioprinter Ships to the University of Cambridge, Ready to "Absolutely Transform the Entire Bioprinting Market"
    About a year ago, a startup called Aether seemed to come right out of the ether, promising a bold new 3D bioprinter with more than 20 swappable extruders.
    3dprint.com
  • Check out this one too, looks perfect for Roche

    https://all3dp.com/aether-ships-first-bioprinter-cambridge-university/

    Aether Ships its First Bioprinter To Cambridge University | All3DP
    On paper, the specifications of the low-cost "Aether 1" bioprinter are very impressive. Now the company has shipped its first beta unit to a science lab in the UK.
    all3dp.com
  • Is Roche looking to buy ECGI, or market ECGI products?
  • this behemoth moves line a snail. something needs to happen with this pos
  • time to spin off the diagnostics division off this dog stock
  • Great stock
  • Enjoy the 3.5% dividend for long term.
  • Posted in $AZN conversation

    AZN expected to enter the growing and crowded cancer immunotherapy market with a mid 2017 filing for Durvalumab. Can they carve out share against the incumbents $MRK, $BMY, and $RHHBY? See our complete analysis of the cancer immunotherapy landscape here: http://bit.ly/2hpP1hw

    Cancer Immunotherapy – Review of a Breakout Year and What to Expect for 2017 / DeciBio | Insights
    Decibio offers expert Mdx market reports, analysis of Life Sciences research tools market trends, NGS market growth reports, and DME market outlook reports.
    bit.ly
  • Is Roche in talks with Ilumina ?